Literature DB >> 11147173

Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis.

D Müller1, A Roessner, C Röcken.   

Abstract

Matrix metalloproteinases (MMPs) degrade basement membranes and connective tissue and play an essential role in the homeostasis of the extracellular matrix which is disrupted by the deposition of amyloid. This immunohistochemical study investigated the distribution pattern of matrix metalloproteinases (MMP-1, -2, -3, and -9) and their inhibitors [alpha 2-macroglobulin (alpha 2-M), tissue inhibitors of MMPs (TIMP)-1, and TIMP-2] in human AA- and AL amyloid deposits. Specimens of liver, kidney, and spleen from 22 autopsy cases were investigated. Nine patients had suffered from generalized AA amyloidosis, eight from generalized AL amyloidosis, and five from rheumatoid arthritis or tuberculosis with no histological evidence of amyloid. In all amyloidotic and non-amyloidotic patients, each protease and protease inhibitor was detected in almost every organ investigated. In the amyloidotic cases, there was no indication that a specific protease or protease inhibitor was absent or expressed, but a difference was observed in their spatial distribution patterns. The most noticeable difference was found in immunostaining of amyloid. Only MMP-1, -2, and -3, and alpha 2-M were present in AA amyloid deposits, and only TIMP-1 and TIMP-2 were found in deposits of AL amyloid. This is the first study to show that MMP-1, -2, and -3 are present in AA amyloid deposits. They may be involved in tissue remodeling or in proteolysis of the precursor and fibril proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147173     DOI: 10.1007/s004280000271

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  10 in total

1.  A putative role for cathepsin K in degradation of AA and AL amyloidosis.

Authors:  C Röcken; B Stix; D Brömme; S Ansorge; A Roessner; F Bühling
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3.

Authors:  B Stix; T Kähne; K Sletten; J Raynes; A Roessner; C Röcken
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation.

Authors:  C Röcken; R Menard; F Bühling; S Vöckler; J Raynes; B Stix; S Krüger; A Roessner; T Kähne
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

4.  Early pathogenesis of cardiac amyloid deposition in senile systemic amyloidosis: close relationship between amyloid deposits and the basement membranes of myocardial cells.

Authors:  Motoji Sawabe; Akihiko Hamamatsu; Tateki Ito; Tomio Arai; Kumiko Ishikawa; Kouji Chida; Naotaka Izumiyama; Naoko Honma; Kaiyo Takubo; Masamitsu Nakazato
Journal:  Virchows Arch       Date:  2003-02-26       Impact factor: 4.064

5.  Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis.

Authors:  Kaushal S Gandhi; Fiona C McKay; Eve Diefenbach; Ben Crossett; Stephen D Schibeci; Robert N Heard; Graeme J Stewart; David R Booth; Jonathan W Arthur
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

Review 6.  Serum amyloid A: an acute-phase protein involved in tumour pathogenesis.

Authors:  E Malle; S Sodin-Semrl; A Kovacevic
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

7.  Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Authors:  Andreia Biolo; Sujata Ramamurthy; Lawreen H Connors; Carl J O'Hara; Hans K Meier-Ewert; Pamela T Soo Hoo; Douglas B Sawyer; David C Seldin; David S Seldin; Flora Sam
Journal:  Circ Heart Fail       Date:  2008-10-14       Impact factor: 8.790

8.  Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis.

Authors:  Christoph Röcken; Rosemarie Kientsch-Engel; Sophie Mansfeld; Barbara Stix; Kay Stubenrauch; Bernd Weigle; Frank Bühling; Mona Schwan; Wolfgang Saeger
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

9.  Matrix Metalloproteinase-9-Generated COOH-, but Not NH2-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity.

Authors:  Mieke Gouwy; Mieke De Buck; Sara Abouelasrar Salama; Jennifer Vandooren; Sofie Knoops; Noëmie Pörtner; Lotte Vanbrabant; Nele Berghmans; Ghislain Opdenakker; Paul Proost; Jo Van Damme; Sofie Struyf
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

10.  Renal Impairment Detectors: IGFBP-7 and NGAL as Tubular Injury Markers in Multiple Myeloma Patients.

Authors:  Karolina Woziwodzka; Jolanta Małyszko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Krzysztof Batko; Paulina Mazur; Małgorzata Banaszkiewicz; Marcin Krzanowski; Paulina Gołasa; Jacek A Małyszko; Ryszard Drożdż; Katarzyna Krzanowska
Journal:  Medicina (Kaunas)       Date:  2021-12-10       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.